Well Referenced

Tag: endocrine health

Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency?

This 2006 editorial by Richard F. Walker explores the therapeutic potential of sermorelin acetate, a synthetic growth hormone-releasing hormone (GHRH) analog, in managing adult-onset growth hormone deficiency (AGHD). Sermorelin acts by stimulating the pituitary to produce endogenous GH, mimicking natural pulsatile secretion, in contrast to direct administration of recombinant human

Read More »
June 26, 2025 No Comments

L-carnitine supplementation for the management of fatigue in patients with hypothyroidism on levothyroxine treatment: a randomized, double-blind, placebo-controlled trial

A randomized, double-blind, placebo-controlled trial investigated the effects of L-carnitine supplementation on fatigue in hypothyroid patients undergoing levothyroxine treatment. Sixty patients (mean age 50.0 ± 9.2 years; 3 males, 57 females) experiencing persistent fatigue (Fatigue Severity Scale [FSS] score ≥36) were randomized to receive either L-carnitine (990 mg twice daily;

Read More »
June 26, 2025 No Comments

Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document

The article titled “Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document” examines the inconsistent benefits of levothyroxine (LT4) and liothyronine (LT3) combination therapy for hypothyroidism, despite its widespread use due to patient-reported benefits. A joint conference by the American, British, and European Thyroid Associations reviewed clinical evidence

Read More »
June 26, 2025 No Comments

Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism?

The article titled “Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism?” from the Journal of Clinical Endocrinology & Metabolism (2012, PMID: 22593590) reviews evidence on combination therapy with levothyroxine (T4) and liothyronine (T3) for hypothyroidism. While standard T4 monotherapy effectively normalizes TSH levels in most patients,

Read More »
June 26, 2025 No Comments

Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects

The observational study titled “Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial,” published in the Journal of Clinical Endocrinology & Metabolism (1970, PMID: 4986007), explored peripheral conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic (thyroid-removed) patients. The findings confirmed the body’s ability

Read More »
June 26, 2025 No Comments

Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study

The randomized controlled trial titled “Dehydroepiandrosterone supplementation enhances immune function in HIV-positive subjects with undetectable viral load” (Clinical Infectious Diseases, 2007, PMID: 17263636) investigated whether supplementation with dehydroepiandrosterone (DHEA) could influence HIV replication and immune function. The study found that DHEA did not significantly alter viral load or CD4+ T-cell

Read More »
June 26, 2025 No Comments

Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men

The randomized, double-blind clinical trial titled “Effects of short-term administration of dehydroepiandrosterone (DHEA) on body composition, cholesterol, and insulin sensitivity in normal men” (Journal of Clinical Endocrinology & Metabolism, 1985, PMID: 25879093) investigated the metabolic impact of high-dose DHEA (1,600 mg/day for 28 days) in five healthy male subjects. DHEA

Read More »
June 26, 2025 No Comments

Dehydroepiandrosterone therapy as female androgen replacement

The article titled “Dehydroepiandrosterone therapy as female androgen replacement” (Seminars in Reproductive Medicine, 2006, PMID: 16633983) reviews the role of dehydroepiandrosterone (DHEA) supplementation as androgen replacement therapy in women, particularly focusing on menopausal and postmenopausal populations. It highlights potential improvements in sexual function, bone mineral density, mood, and overall well-being,

Read More »
June 26, 2025 No Comments